Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features

Childs Nerv Syst. 2010 Jan;26(1):137-43. doi: 10.1007/s00381-009-0995-3. Epub 2009 Oct 13.

Abstract

Introduction: Childhood glioblastoma multiforme (GBM) is uncommon, accounting for 7.2% of the central nervous system tumors in childhood. Their clinical behaviors are almost as aggressive as those in adults, and the 5-year overall survival rate is poor.

Case report: We describe a case of a 13-year-old boy with GBM. Fourteen months after surgical resection followed by radiotherapy and temozolomide chemotherapy, the patient showed local recurrence. No response to subsequent bevacizumab treatment was observed. To determine correlations of molecular alterations with clinical outcomes in this case, we examined the expressions of Ki-67, MMP-9, MGMT, VEGF, Ras, and p-AKT using biopsies before and after recurrence.

Discussion: Childhood glioblastomas show a distinct biological behavior and probably a different molecular pathogenesis in comparison to the adult ones. Understanding the molecular mechanisms responsible for the formation and progression of the tumors is critical for identification of novel therapeutic targets.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Bevacizumab
  • Brain / metabolism
  • Brain / pathology
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy
  • Dacarbazine / analogs & derivatives
  • Dacarbazine / therapeutic use
  • Glioblastoma / drug therapy*
  • Glioblastoma / pathology
  • Glioblastoma / therapy
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Neoplasm Recurrence, Local / drug therapy*
  • Temozolomide

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Alkylating
  • Bevacizumab
  • Dacarbazine
  • Temozolomide